Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088654 · ClinicalTrials.gov registry record · Phase 1
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Innate Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
- 14
- Study locations
NCT06088654: Recruiting Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Innate Pharma.
NCT06088654 is a Phase 1 study of Non-Hodgkin Lymphoma that is actively recruiting participants, run by Innate Pharma. The registered enrollment target is 184 participants, above the 166-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (11% higher). The trial reports 14 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06088654, a Phase 1 study of Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Innate Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.
Primary Outcome
To evaluate the safety profile (including dose limiting toxicities (DLT(s), the maximum tolerated dose (MTD) or highest tested dose), tolerability and determine the recommended phase 2 dose (RP2D)
Conditions Studied
Interventions
- DRUG IPH6501
Study Locations (14)
Other
- Austin Health - Heidelberg
- Institute Bergonie - Bordeaux
- Centre Hospitalier Regional Universitaire de Lille - Lille
- Hospices Civils de Lyon - Lyon
- Hôpital de la Coception - Marseille
- Centre Hospitalier Universitaire de Nantes - Nantes
California
- City of Hope - Duarte
- Cedars Sinai - Los Angeles
New York
- Icahn School Of Medicine At Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Victoria
- Monash Health - Clayton
- Peninsula Private Hospital - Frankston
Missouri
- Siteman Cancer Center - St Louis
New South Wales
- Wollongong Private Hospital - Wollongong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT06088654 shows while recruiting
NCT06088654 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which IPH6501 is the first listed.
NCT06088654 lists 14 locations in 6 states (Other, California, New York).
Frequently Asked Questions
What is clinical trial NCT06088654 about?
NCT06088654 is a clinical study titled "Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma". This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.
What is the current status of trial NCT06088654?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2024-03-04. Estimated completion is 2028-12-31.
What conditions does trial NCT06088654 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06088654?
The interventions under investigation include: IPH6501 (DRUG).
Who is sponsoring clinical trial NCT06088654?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088654 being conducted?
This trial has 14 study locations across California, Missouri, New York, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06088654's enrollment target sits among peer trials
184 22nd of 106 higher than 85 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI